Peer-Reviewed Publications
1977
1. Ratner L, Sen GC, Brown GE, Lebleu B, Kawakita M, Cabrer B, Slattery E, Lengyel P. 1977. Interferon: double-stranded RNA and RNA degradation: characteristics of an endonuclease activity. Eur J Biochem 79:565-577.
1978
2. Ratner L, Wiegand RC, Farrell PJ, Sen GC, Cabrer B, Lengyel P. 1978. Interferon: double-stranded RNA and RNA degradation: fractionation of the endonculease-INT into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun 81:947-954.
3. Farrell PJ, Sen GC, DuBois MF, Ratner L, Slattery E, Lengyel P. 1978. Interferon action: two distinct pathways for the inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci USA 75:5893-5897.
1979
4. Jarvis AP, White C, Ball A, Gupta SL, Ratner L, Sen GC, Colby C. 1979. Interferon-associated dsRNA-dependent enzyme activities in a mutant 3T6 cell engaged in the semi-constitutive synthesis of interferon. Cell 14:879-887.
5. Ratner L. 1979. Studies of interferon action: (A) Characteristics of a double-stranded RNA activated endoribonuclease; (B) Effect on cell replication. PhD thesis, Yale University.
1980
6. Ratner L, Nordlund JJ, Lengyel P. 1980. Interferon as an inhibitor of cell growth: studies with mouse melanoma cells. Proc Soc Exp Biol Med 163:267-272.
1984
7. Josephs SF, Chan G, Ratner L, Wong-Staal F. 1984. Human proto-oncogene corresponding to the transforming region of the simian sarcoma virus. Science 223:487-491.
8. Clarke MF, Westin E, Schmidt D, Josephs SF, Ratner L, Wong-Staal F, Gallo RC, Reitz MS. 1984. Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature 308:464-467.
9. Josephs S, Ratner L, Clarke MF, Westin EH, Reitz MS, Wong-Staal F. 1984. Transforming potential of the normal human c-sis nucleotide sequences encoding a chain of platelet-derived growth factor. Science 225:636-639.
1985
10. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF,Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
11. Starcich B, Ratner L, Josephs SF, Okamoto T, Gallo RC, Wong-Staal F. 1985. Characterization of the long terminal repeat sequences of the AIDS virus, human T-cell leukemia (lymphotropic) virus type III (HTLV-III). Science 227:538-540.
12. Ratner L, Josephs SF, Starcich B, Hahn B, Shaw GM, Gallo RC, Wong-Staal F. 1985. Nucleotide sequence analysis of a variant human T-cell leukemia virus (HTLV-Ib) provirus with a deletion in pX-I. J Virology 54:781-790.
13. Ratner L, Gallo RC, Wong-Staal F. 1985. HTLV-III, LAV, ARV are variants of the same AIDS virus. Nature 313:636-637.
14. Fisher AG, Collalti E, Ratner L, Gallo RC, Wong-Staal F. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262-265.
15. Ratner L, Josephs SF, Jarrett R, Reitz MS, Wong-Staal F. 1985. Nucleotide sequence of transforming human c-sis cDNA clones with homology to platelet-derived growth factor. Nucl Acids Res 13:5007-5018.
16. Ratner L, Starcich B, Josephs SF, Hahn BH, Reddy EP, Livak KJ, Petteway SR, Pearson ML, Haseltine WA, Arya SK, Wong-Staal F. 1985. Polymorphism of the 3’open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucl Acids Res 13:8219-8229.
1986
17. Seigel LJ, Ratner L, Josephs SF, Derse D, Feinberg M, Reyes G, O’Brien SJ, Wong-Staal F. 1986. Transactivation induced by human T-lymphotropic virus type III (HTLV-III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity. Virology 148:226-228.
18. Ratner L, Wesley R, Peylan-Ramu N, Poplack DG. 1986. Adverse prognostic influence of hepatitis in acute lymphoblastic leukemia. Cancer 58:1096-1100.
19. Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME, Broder S, Gallo RC, Wong-Staal F. 1986. Infectious mutants of HTLV-III with changes in the 3’open region and markedly reduced cytopathic effects. Science 233:655-659.
20. Ratner L. 1986. Delta hepatitis outbreak in a group of leukemia patients. Ann Int Med 105:992.
1987
21. Ratner L, Griffith RC, Marselle L, Hoh M, Wong-Staal F, Saxinger C. 1987. A lymphoproliferative disorder caused by human lymphotropic virus type I: demonstration of a continuum between acute and chronic adult T-cell leukemia/lymphoma. Am J Med 83:953-958.
22. Ratner L, Fisher A, Jagodzinski LL,Mitsuya H, Liou R-S,Gallo RC, Wong-Staal F. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retrovir 3:57-67.
23. Thielan BJ, Hunter E, Desrosiers RC, Ratner L. 1987. Transactivation of long terminal repeat sequence-mediated gene expression is not a general property of type D retrovirus replication. J Gen Virology 68:2265-2270.
24. Ratner L, Polmar S, Paul N, Ruddle NH. 1987. Cytotoxic factors secreted by human immunodeficiency virus type I infected cells. AIDS Res Hum Retrovir 3:147-150.
25. Ratner L, Thielan BJ, Collins TC. 1987. Sequences of the 5’portion of the human c-sis gene: characterization of the transcriptional promoter and regulation of expression of the protein product by 5’untranslated mRNA sequences. Nucl Acids Res 15:6017-6036.
26. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F. 1987. The sor gene of HIV-1 modulates virus propagation in vitro. Science 237:888-893.
1988
27. Ratner L, Poiesz BJ. 1988. Leukemias associated with human T-cell lymphotropic virus type I in a non-endemic region. Medicine 67:400-422.
1989
28. Ratner L. 1989. Regulation of expression of the c-sis proto-oncogene. Nucl Acids Res 17:4101-4115.
29. Bell J, Ratner L. 1989. Specificity of the polymerase chain amplification reaction for HIV-1 DNA sequences. AIDS Res Hum Retrovir 5:87-95.
30. Niederman T, Thielan BJ, Ratner L. 1989. Human immunodeficiency virus type 1 negative factor (nef) is a transcriptional silencer. Proc Natl Acad Sci USA 86:1128-1132.
31. Lee S-J, Hu W, Fisher AG, Looney DJ, Mitsuya H, Ratner L, Wong-Staal F. 1989. Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retrovir 5:441-449.
32. Dedera D, Hu W, Vander Heyden N, Ratner L. 1989. Viral protein R (VPR) of human immunodeficiency virus type 1 and 2 is dispensable for replication and cytopathicity in lymphoid cells. J Virology 63:3205-3208.
33. Vander Heyden N, Rodi C, Ratner L. 1989. Analogs of 3’amino-3′-deoxyadenosine inhibit HIV-1 replication. AIDS Res Hum Retrovir 5:647-653.
34. Hu W, Vander Heyden N, Ratner L. 1989. Analysis of the function of viral protein X (VPX) of HIV-2. Virology 173:624-630.
35. Bryant ML, Heuckeroth RO, Kimata JT, Ratner L, Gordon JI. 1989. Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc Natl Acad Sci USA 86:8655-8659.
1990
36. Bryant M, Ratner L. 1990.Myristoylation-dependent replication and assembly of HIV-1. Proc Natl Acad Sci USA 87:523-527.
37. McNearney T, Westervelt P, Thielan BJ, Trowbridge DB, Garcia J, Whittier R, Ratner L. 1990. Limited sequence heterogeneity among biologically distinct HIV-1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci USA 87:1917-1921.
38. Ratner L, Vander Heyden N, Paine E, Frei-Lahr D, Brown R, Petruska P, Reddy S, Lairmore MD. 1990. Familial adult T-cell leukemia/lymphoma. Am J Hematol 34:215-222.
39. Dedera D, Vander Heyden N, Ratner L. 1990. Attenuation of HIV-1 infectivity by an inhibitor of oligosaccaride processing. AIDS Res Hum Retrovir 6:785-794.
40. Smidt M, Kirsch I, Ratner L. 1990. Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. J Clin Invest 86:1151-1157.
41. Griffith RC, Saha BK, Janney CM, Ratner L, Brunt EM, Gajl-Peczalska KJ, Hanto DW. 1990. Immunoblastic lymphoma of T-cell type in a chronically immunosuppressed renal transplant recipient. Am J Clin Pathol 93:280-285.
1991
42. Bryant ML, Ratner L, Duronio RJ, Kishore NS, Adams SP, Gordon JI. 1991. Incorporation of 12-methoxydodecanoate into the gag polyprotein precursor of HIV-1 inhibits its proteolytic processing as well as virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci USA 88:2055-2059.
43. Westervelt P, Gendelman HE, Li Y, Ratner L.1991. A determinant within the HIV-1 gp120 envelope protein critical for infection of primary monocytes. Vaccines 91, Cold Spring Harbor Laboratory Press, pp 71-76.
44. Ratner L, Vander Heyden N, Dedera D. 1991. Inhibition of HIV & SIV infectivity by blockade of alpha-glucosidase activity. Virology 181:180-192.
45. Ratner L, Vander Heyden N, Garcia J, Polinsky M, Westervelt P, Becich M. 1991. Formation of non-infectious HIV-1 virus particles lacking a full length envelope protein. AIDS Res Hum Retrovir 7:287-294.
46. Paine E, Garcia J, Philpott TC, Shaw G, Ratner L 1991. Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients. Virology 182:111-123.
47. Westervelt P, Gendelman HE, Ratner L. 1991. Identification of a determinant within the HIV-1 surface envelope glycoprotein critical for productive infection of cultured primary monocytes. Proc Natl Acad Sci USA 88:3097-3101.
48. Niederman TMJ, Hu W, Ratner L. 1991. Simian immunodeficiency virus negative factor (NEF) suppresses the level of viral mRNA in COS cells. J Virology 65:3538-3546.
49. Kimata JT, Ratner L. 1991. Temporal regulation of viral and cellular gene expression during HTLV-I mediated lymphocyte immortalization. J Virology 65:4398-4407.
50. Ratner L, Philpott T, Trowbridge DB. 1991. Nucleotide sequence analysis of isolates of human T-lymphotropic virus type 1 of diverse geographic origins. AIDS Res Hum Retrovir 7:923-941.
51. Smidt M, Dumanski JP, Collins VP, Ratner L. 1991. Structure and expression of the c-sis gene and its relationship to sporadic meningiomas. Cancer Res 51:4295-4298.
52. Dedera D, Ratner L. 1991. Demonstration of two distinct cytopathic effects with syncytia-defective HIV-1 mutants. J Virology 65:6129-6136.
1992
53. Dedera D, Gu R, Ratner L. 1992. Conserved cysteine residues in the HIV-1 transmembrane envelope protein are essential for precursor envelope cleavage. J Virology 66:1207-1209.
54. Dedera D, Gu R, Ratner L. 1992. Role of asparagine-linked glycosylation in human immunodeficiency virus type 1 transmembrane envelope protein. Virology 187:377-381.
55. Westervelt P, Trowbridge DB, Epstein LG, Blumberg GM, Li Y, Hahn BH, Shaw GM, Price RW, Ratner L. 1992. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virology 66:2577-2582.
56. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J. Gendelman HE, Ratner L. 1992. Dual regulation of silent and productive infection in monocytes by distinct HIV-1 determinants. J Virology 66:3925-3931.
57. McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A, Ratner L. 1992. Relationship of HIV-1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 89:10247-10251. PMCID: PMC53595
58. Niederman TMJ, Garcia VJ, Hastings WR, Luria S, Ratner L. 1992. Human immunodeficiency virus type 1 nef protein inhibits NF -kB induction in human T-cells. J Virology 66:6213-6219.
1993
59. McNearney T, Hornickova Z, Kloster B, Birdwell A, Stroch GA, Polmar SH, Arens M, Ratner L. 1993. Evolution of sequence divergence among human immunodeficiency virus type 1 isolates derived from a blood donor and a recipient. Ped Res 33:36-42.
60. Ratner L, Vander Heyden N. 1993. Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs. AIDS Res Hum Retrovir 9:291-297.
61. Niederman TMJ, Hastings WR, Luria S, Bandres JC, Ratner L. 1993. Human immunodeficiency virus type 1 nef protein inhibits the recruitment of AP-1 DNA binding activity in human T-cells. Virology 194:338-344.
62. Ebenbichler CF, Roder C, Vornhagen R, Ratner L, 1993. Dierich M. Cell surface proteins binding to recombinant soluble HIV-1 and HIV-2 transmembrane proteins. AIDS 7:489-495.
63. Kimata JT, Palker TJ, Ratner L 1993. The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and mediated by the CD2/LFA-3 activation pathway. J Virology 67:3134-3141.
64. Ebenbichler CF, Westervelt P, Carrillo A, Henkel T, Johnson D, Ratner L. 1993. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations. AIDS 7:639-646.
65. Niederman T, Hastings WR, Ratner L. 1993. Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology 197:420-425.
66. Murti KG, Brown PS, Ratner L, Garcia JV. 1993. Highly localized tracts of HIV-1 Nef in the nucleus of cells of a human CD4+ T cell line. Proc Natl Acad Sci USA 90:11895-11899.
67. Gu R, Westervelt P, Ratner L. 1993. Role of HIV-1 envelope V3 loop cleavage in cell tropism. AIDS Res Hum Retrovir 9:1007-1015.
68. Lu Y-L, Spearman P, Ratner L. 1993. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virology 67:6542- 6550.
69. Arens M, Josephs T, Nag S, Miller JP, Powderly WG, Ratner L. 1993. Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retrovir 9:1251-1257.
70. Carrillo A, Trowbridge DB, Westervelt P, Ratner L. 1993. Identification of HIV-1 determinants for T lymphoid cell line infection. Virology 197:817-824.
1994
71. Bandres JC, Ratner L. 1994. Human immunodeficiency virus type 1 nef protein down-regulates transcription factor NF -kB and AP-1 in human T-cells in vitro through a protein kinase c dependent mechanism. J Virology 68:3243-3249.
72. Horton R, Spearman P, Ratner L. 1994. HIV-2 viral protein X association with the gag p27 capsid protein. Virology 199:453-457.
73. Paine EP, Gu R, Ratner L. 1994. Structure and expression of the human T-cell leukemia virus type 1 envelope protein. Virology 199:331-338.
74. Spearman P, Wang JJ, Vander Heyden N, Ratner L. 1994. Identification of HIV-1 gag protein domains essential to membrane binding and particle assembly. J Virology 68:3232-3242.
75. Kimata JT, Wong F-H, Ratner L. 1994. CD3-dependent lymphocyte activation by human T-cell leukemia virus type I-producing cells. J Gen Virology 74:2433-2437.
76. Yu X, McLane M-F, Ratner L, O’Brien W,Collman R, Essex M, Lee T-H. 1994. Killing of primary CD4+ cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91:10237-10241.
77. Wang JJ, Lu Y-L, Ratner L. 1994. Viral assembly and expression of vpr in human immunodeficiency virus type 1 demonstrated by immunoelectron microscopy. J Gen Virology 75:2607-2614.
78. Bandres JC, Luria S, Ratner L. 1994. Regulation of human immunodeficiency virus Nef protein by phosphorylation. Virology 201:157-161.
79. Heinzinger N, Bukrinsky M, Haggerty S, Ragland A, Lee M-A, Kewalramani V, Gendelman H, Ratner L, Stevenson M, Emerman M. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91:7311-7315.
80. Kimata JT, Wong F-H, Wang JJ, Ratner L. 1994. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology 204:656-664.
1995
81. Bandres JC, Shaw AS, Ratner L. 1995. HIV-1 nef protein downregulation of CD4 surface expression: relevance of the lck binding domain of CD4. Virology 207:338-341.
82. Grossman WJ, Kimata JT, Wong F-H, Zutter M, Ley TJ, Ratner L. 1995. Development of leukemia in mice transgenic for the tax gene of HTLV-I. Proc Natl Acad Sci USA 92:1057-1061
83. Henkel T, Westervelt P, Ratner L. 1995. HIV-1 V3 envelope sequences required for macrophage infection. AIDS 9:399-401.
84. Paredes J, Kahn JO, Tong W, Feldstein ML, Bennett JM, Metroka CE, Ratner L, Krown S. 1995. Weekly oral etoposide in patients with Kaposi sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group. J Acq Immune Defic Syndr 9:138-144.
85. McNearney T, Hornickova Z, Templeton A, Birdwell A, Arens M, Markham R, Ratner L. 1995. Nef and LTR sequence variation from sequentially derived human immunodeficiency virus type 1 isolates. Virology 208:388-398.
86. Lu Y-L, Bennett R, Wills J, Gorelick R, Ratner L. 1995. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virology, 69:6873-6879.
87. Ebenbichler C, McNearney T, Stoiber H, Most J, Zangerle R, Vogetseder W, Patsch JR, Ratner L, 1995. Dierich MP. Sera from HIV-1 infected individuals in all stages of disease preferentially recognize the V3 loop of the prototypic macrophage-tropic glycoprotein gp120 ADA. Mol Immunol 32: 1039-1045.
1996
88. Carrillo A, Ratner L. 1996. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virology, 70:1301-1309.
89. Carrillo A, Ratner L. 1996. Cooperative effects of the HIV-1 envelope variable loops V1 and V3 in mediating infectivity for T-lymphoid cell lines. J Virology, 70:1310-1316.
90. Spearman P, Ratner L. 1996. Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J Virology. 70: 8187- 8194.
91. Ratner L, Joseph T, Bandres J, Ghosh S, Vander Heyden N, Templeton A, Hahn B, Powderly W, Arens M. 1996. Sequence heterogeneity of Nef transcripts in HIV-1-infected subjects at different stages of disease. Virology, 223: 245-250.
92. Trejo S, Fahl W, Ratner L. 1996. c-sis/PDGF-B promoter transactivation by the Tax protein of human T-cell leukemia virus type 1. J Biol Chem, 271:14584-14590.
93. Yahi N, Ratner L, Harouse JM, Gonzalez-Scarano F, Fantini J. 1996. Genetic determinants controlling HIV-1 tropism for CD4/GalCer+ human intestinal epithelial cells: importance of the V3 loop. Perspective in Drug Discovery & Design, 5: 161-168.
94. Collins ND, Newbound GC, Ratner L, Lairmore MD. 1996. In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotropic virus type 1 (HTLV-1). J Virology, 70: 7241-7246.
1997
95. Trejo SR, Fahl WE, Ratner L. 1997. The tax protein of human T-cell leukemia virus type 1 mediates the transactivation of the c-sis/PDGF B promoter through interactions with the zinc finger transcription factors Sp1 and Egr-1. J Biol Chem, 272:27411-27421.
96. Spearman P, Horton R, Ratner L, Kuli-Zade I. 1997. Membrane binding of HIV-1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virology, 71:6582-6592.
97. Grossman W, Ratner L. 1997. Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood, 90: 783-794.
1998
98. Popov S, Rexach M, G. Zybarth, N. Reiling, Lee M-A, Ratner L, CM Lane, MS Moore, Blobel G, Bukrinsky M. 1998. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. EMBO J, 17: 909-917
99. Zhou Y, Lu Y, Ratner L. 1998. Arginine residues in the HIV-1 Vpr C-terminal domain are important for nuclear localization and cell cycle arrest. Virology. 242:414-424
100.Pancio H, Ratner L. 1998. Human immunodeficiency virus type 2 Vpx-Gag interaction. J Virology, 72:5271-5275.
101. Albrecht B, Collins N, Ratner L, and Lairmore M. 1998. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virology Methods, 75:123-140.
102. Robek L, Wong F-H, and Ratner L. 1998. Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J Virology, 72:4458-4462.
103. Collins N, Ratner L, and Lairmore M. 1998. Selective ablation of human T-cell lymphotropic virus type 1 p12-I reduces viral infectivity in vivo. Blood, 91:4701-4707.
104. Popov S, Rexach M, Ratner L, Blobel G, and Bukrinsky M. 1998. Viral protein R regulates docking of the HIV-1 preintegation complex to the nuclear pore complex. Journal of Biological Chemistry 273:13347-13352.
105. Garnier L, Ratner L, Rovinski B, Wills JW. 1998. Particle size determinants in the human immunodeficiency virus type 1 gag protein. J Virology 72: 4667-4677
1999
106. Wang JJ, Horton R, Varthakavi V, Spearman P, Ratner L. 1999. Formation and release of virus-like particles by HIV-1 matrix protein. AIDS, 13:281-283.
107. Vocero-Akbani AM, Vander Heyden N, Lissy NA, Ratner L, Dowdy SF. 1999. Killing of HIV infected cells by transduction with an HIV protease-activated caspase-3 protein. Nature Medicine, 5:29-33.
108. Grossman WJ, Verbsky J, Tomis D, Yang L, Berg L, Fields LE, Chaplin DD, Ratner L. 1999. Dysregulated myelopoiesis in mice deficient in Jak3. Blood, 94:1-9.
109. Voulgaropoulou F, Tan B, Soares M, Hahn B, Ratner L. 1999. Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. J Virology 73:3497-3504.
110. Robek MD, Ratner L. 1999. Immortalization of CD4(+) and CD8(+) lymphocytes by human T-cell leukemia virus type 1 tax mutants expressed in a functional molecular clone. J Virology 73:4856-4865
111. Collins ND, D’Souza C, Albrecht B, Robek MD, Ratner L, Ding W, Green PL, Lairmore MD. 1999. Proiliferation response to interleukin 2 and Jak/Stat activation of T-cells immortalized by human T-lymphotropic virus type 1 is independent of open reading frame 1 expression. J Virologyogy 73:9642-9649.
112. Hung C-S, Vander Heyden N, Ratner L. 1999. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virology 73:8216-8226.
113. Hung C-S, Pontow S, Ratner L. 1999. Relationship between productive HIV-1 infection of macrophages and CCR5 utilization. Virology 264:278-288.
2000
114. Pirounaki M, Vander Heyden NA, Arens M, Ratner L. 2000. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. J Virology Methods, 85:151-161. PMID:10725200
115. Trejo S, Ratner L. 2000. The HTLV receptor is a widely expressed protein. Virology, 268:41-48
116. Pancio H, Vander Heyden N Ratner L. 2000. The C-terminal proline-rich tail of HIV-2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J Virology 74:6162-6167.
117. Pancio H, Vander Heyden N, Kosuri K, Cresswell P, Ratner L. 2000. Interaction of HIV-2 Vpx with invariant chain. J Virology, 74:6168-6172.
118. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani B, Ratner L. 2000. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). Journal of AIDS, 24:444-450.
119. Bartoe JT, Albrecht B, Collins ND, Robek MD, Ratner L, Green PL, Lairmore MD. 2000. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virology, 74:1094-1100.
120. Voulgaropoulou F, Pontow SE, Ratner L. 2000. Productive infection of CD34+ cell derived megakaryocytes by X4 and R5 HIV-1 isolates. Virology, 269:78-85.
121. Deora A, Spearman P, Ratner L. 2000. The N-terminal matrix domain of HIV-1 gag is sufficient for viral protein U (Vpu) mediated enhancement of particle release through a membrane targeting mechanism. Virology, 269:305-312.
122. Khanna KV, Yu X-F, Ford D, Ratner L, Hildreth JK, Markham RB. 2000. Differences among HIV-1 variants in their ability to elicit secretion of TNF-alpha. J Immunology, 164:1408-1415.
123. Zhou Y, Ratner L. 2000. Phosphorylation of HIV-1 Vpr regulates cell cycle arrest. J Virology, 74:6520-6527.
124. Derdeyn CA, Decker JM, Sfakianos JN, Kappes JC, O’Brien WA, Ratner L, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virology, 74:8358-8367.
125. Robek M, Ratner L. 2000. Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction. J Virology, 74:11988-11992.
126. Albrecht B, Collins ND, Burniston MT, Nisbet JW, Ratner L, Green PL, Lairmore MD. 2000. Human T-lymphotropic virus type 1 (HTLV-1) ORF I p12-I is required for efficient viral infectivity in primary lymphocytes. J Virology, 74:9828-9835.
2001
127. Jin L, Zhou Y, Ratner L. 2001. HIV-2 Vpx interaction with gag and incorporation into virus-like particles. AIDS Research & Human Retroviruses, 17:105-111.
128. Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LWA, Dosik H, Cunningham C, Montagna R. 2001. Prevalence of HTLV-1 associated T-cell lymphoma. Am J Hematol 66:32-38
129. Deora A, Ratner L. 2001. Viral protein U (Vpu) mediated enhancement of HIV-1 particle release depends on the rate of cellular proliferation. J Virology, 75:6714-6718
130. Portis T, Harding J, Grossman, W,J, Ratner L. 2001.Analysis of p53 inactivation in human T-cell leukemia virus type 1 tax transgenic mouse model. J Virology, 75:2185-2193
131. Zhou Y, Ratner L. 2001. A novel inducible system to study transdominant mutants of HIV-1 Vpr, Virology.287:133-142
132. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D, for the AIDS Malignancy Consortium. 2001. Chemotherapy for HIV-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol, 19:2171-2178.
133. Portis T, Harding JC, Ratner L. 2001. The contribution of NF kB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 (HTLV-1) tax-induced tumors. Blood, 98:1200-1208.
134. Derdeyn CA, Decker JM, Sfakianos JN, O’Brien WA, Ratner L, Shaw GM, Hunter E. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor J Virology 75:8605-8614
135. Tsukahara T, Ratner L. 2001. Characterizataion of envelope glycoprotein mutants for HTLV-1 infectivity and immortalization. J Virology 75:9553-9559
136. Pontow S and Ratner L. 2001. Evidence for common structural elements in the HIV-1 gp120 binding site provided through functional analysis of CCR5/CXCR4 chimeric coreceptors. J Virology, 75:11503-11514 PMCID: PMC114737
137. Wang JJ and Ratner L. 2001. Effect of mutant Vpr/Vpx on HIV-2 assembly demonstrated by immunoelectron microscopy. Proc. Natl. Sci. Counc. Repub. China B. 25:50-58.
138. Wang JJ, Standefur S, Spearman P, Chiou CT, Chiang PH, Ratner L. 2001. Tracking the assembly pathway of human immune-deficiency virus type 1 gag deletion mutants by immunogold labeling. Applied Immunohistochemistry & Molecular Morphology, 9:371-379
2002
139. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. 2002. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma:A phase I AIDS Malignancy Consortium Study, J Clin Oncol, 20:153-159.
140. Liu Y, Dole K, Stanley JRL, Richard V, Rosol TJ, Ratner L, Lairmore M, Feuer G. 2002. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in scid/bg and nod/scid mice. Leuk Res, 26:561-567.
141. Yang L and Ratner L. 2002. Interaction of HIV-1 Gag and membranes in a cell-free system. Virology, 302:164-173.
142. McGinn TM, Tao B, Cartner S, Schoeb T, Davis I, Ratner L, Fultz PN. 2002. Association of primate T-cell lymphotropic virus infection of pig-tailed macaques with high mortality. Virology 304:364-378.
2003
143. Belshan M, Ratner L. 2003. Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx. Virology, 311:7-15.
144. Feng X, Vander Heyden, N, Ratner L. 2003. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virology, 77:13389-13395.
2004
145. Pontow S, Vander Heyden NA, Wei S, Ratner L. 2004. Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. J Virology, 78:7138-7147. PMCID: PMC421652
146. Tsukahara T, Ratner L. 2004. Substitution of HIV-1 Nef with HTLV-1 p12, AIDS Res & Hum RetroVirology 20:938-943
147. Silverman LR, Nisbet JW, Phipps AJ, Ratner L, Lairmore, MD. 2004. Human T-lymphotropic virus type I open reading frame II encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virology 78:3837-3845
148. Kaushik R, Ratner L. 2004. Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J. Virology. 78: 2319-2326
149. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. 2004. Enhanced tumorigenesis in HTLV-1 Tax transgenic mice deficient in interferon gamma. Blood, 104:3305-3311. PMID:15090453
150. Mitra-Kaushik S, Harding J, Hess J, Ratner L, 2004. Effects of the proteasome inhibitor, PS-341, on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood, 104: 802-809.
151. Benko Z, Liang D, Agbottah E, Hou J, Chiu K, Yu M, Innis S, Reed P, Kabat W, Elder RT, DiMarzio P, Ratner L, Young PG, Bukrinksy M, Zhao Y. 2004. Anti-Vpr activity of a yeast chaperone protein. J Virology, 78:11016-11029
2005
152. Wielgosz MM, Rauch DA, Jones KS, Ruscetti FW, Ratner L. 2005. Cholesterol-dependence of HTLV-1 infection, AIDS Research & Human Retroviruses, 21:43-50. PMCID: PMC2671014
153. Silverman L, Phipps A, Montgomery A, Fernandez S, Tsukahara T, Ratner L, and Lairmore M. 2005. In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface unit mutations. Blood 106:3602-3608.
154. FracassoPM, Blum KA, Ma MK, Tan BR, Arquette MA, Picus J, Denes A, Mortimer JE, Wright LP, Goodner SA, Fears CL, Hou V, Ratner L, Ivy SP, McLeod HL. 2005. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Brit J Cancer 93:46-53.
155. Gao L, Dheng H, Zhao H, Hirbe A, Ratner L, Weilbaecher K. 2005. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone disease prevented by osteoclast inhibiton. Blood 106:4294-4302.
2006
156. Aboulafia DM, Ratner L, Miles SA, Lee JY, Harrington WJ for the AIDS Malignancy Consortium. 2006. Antiviral and immunomodulatory treatment for HIV-associated primary central nervous system lymphoma: AIDS Malignancy Consortium Pilot Study 019, Clin Lymphoma Myeloma 6:399-402
157. Hiraragi H, Kim S-J, Phipps AJ, Silic-Benussi M, Ciminale V, Ratner L, Green PL, Lairmore MD. 2006. Human T-lymphotropic virus type 1 mitochondria localizing protein p13-II is required for viral infectivity in vivo, J Virology, 80:3469-3476.
158. Belshan M, Mahnke L, and Ratner L. 2006. Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. Virology, 346:118-126.
159. Mahnke LA, Belshan M, and Ratner L. 2006. Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. Virology 348:165-174.
160. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. 2006. HIV-1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virology.80:750-8.
161. Bernal-Mizrachi L, Lovly CM, Ratner L. 2006. The role of nuclear factor kB-1 and -2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci, 103:9220-9225.
162. Michael B, Hiraragi H, Datta A, Ratner L, Lairmore MD. 2006. Histone acetyltransferase (HAT) activity of p30 modulates HTLV-1 p30II – mediated repression of LTR transcriptional activity Virology, 354:225-39.
163. Grant C, Oh U, Fugo K, Takenouchi N, Griffith C, Yao K, Newhook TE, Ratner L, Jacobson S. 2006. Foxp3 represses retroviral transcription by targeting both the NFkB and CREB pathways. PLOS Pathogens. 2:0303-0314
2007
164. Datta A, Silverman L, Hiraragi H, Phipps A, Hiraragi H, Ratner L, 2007. Lairmore M. Human T-lymphotropic virus type 1 p30II expression alters cell cycle G2 regulation in T lymphocytes, RetroVirology 4:49. PMCID: PMC1937004
165 Ramos JC, Ratner L, Harrington WJ. 2007. IRF-4 and c-Rel expression in antiviral therapy resistant adult T-cell leukemia/lymphoma. Blood, 109:3060-3068. PMCID: PMC1852214
166. Pontow S, Harmon B, Campbell N, Ratner L. 2007. Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIVfusion assay, Virology. 368:1-6. PMCID: PMC2174213
167. Bhatia A, Campbell N, Panganiban A, Ratner L. 2007. Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix, Virology, 369(1):47-54. PMCID: PMC2211416
168. Ratner L, Grant C, Zimmerman B, Fritz J, WeilG, Denes A, Suresh R, Campbell N, Jacobson S, Lairmore M. 2007. Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. Am J Hematol., 82(10):929-31. PMCID: PMC2652703
2008
169. Salim A, Ratner L. 2008. Modulation of β-catenin and E-cadherin interaction by Vpu increases HIV-1 particle release. J. Virol. 82:3932-3938. PMCID: PMC2292983
170. Cheng X, Belshan M, Ratner L. 2008. Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex. J Virol. 82: 1229-1237. PMCID: PMC2224430
171. Feng X, Ratner L. 2008. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virol. 374:210-216. PMCID: PMC2373983
172. Harmon B, Ratner L. 2008. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J Virology, 82:9191-9205. PMCID: PMC2546909
2009
173. Gross S, Rauch D, Harding J, Heinecke JW, Ratner L, Piwnica-Worms D. 2009. Bioluminescence imaging of myeloperoxidase activity in vivo, Nature Med, 15:455-461. PMCID: PMC2831476
174. Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. 2009. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood, 113:1493-1500. PMCID: PMC2644076
175. Bhatia A, Kaushik R, Pontow S, Vander Heyden N, Ratner L. 2009. Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virologyogy, 384:233-241 PMCID: PMC2651518.
176. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M, for the AIDS Malignancy Consortium. 2009. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLOS One, 4:e4429, PMCID: PMC2636875.
177. Taylor JM, Brown M, Nejmeddine M, Kim KJ, Ratner L, Lairmore M, Bangham C, Nicot C. 2009. Novel role for IL2R-Jak signaling in retrovirus virion maturation and infectivity. J Virology, 83:11467-11476; PMCID: PMC2772716
178. Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. 2009. T-cell activation promotes tumorigenesis in inflammation-associated cancer. RetroVirology, 6:116 PMCID: PMC2806367
179. Lodewick J, Polania A, Lamsoul I, Lebrun S, Burny A, Ratner L, Bex F. 2009. Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-κB pathway and completion of mitosis. Virology, 386:68-78. PMCID: PMC2834172
180. Mansouri S, Sarzala P, Choudhary G, Ratner L, and Hudak KA. 2009. Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. J Biol Chem, 284:31453-31462; PMCID: PMC2781541
181. Lechowicz MJ, Dittmer, DP, Lee JY, Dezube B, Ratner L, Wachsman W, Aboulafia D, Krown SE, Said J, Ambinder RF. 2009. Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic acid. Clin Inf Dis, 49:1946-1949.
2010
182. Zhang M, Evans S, Yuan J, Ratner L, and Koka PS. 2010. HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelop gp120 V3 loop region. Virology, 401:131-136, PMCID: PMC2862081
183. Harmon B, Campbell N, Ratner L. 2010 Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLOS Pathogens, 6:e1000956, PMCID: PMC2887473
184. Sparano JA, Lee J, Kaplan LD, Levine A, Harrington W, Ambinder R, Wachsman W, Aboulafia D, Noy A, Henry D, Von Roenn J, Dezube B, Remick S, Shah M, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. 2010. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective without excessive toxicity in HIV-associated, B-cell non-Hodgkin’s lymphoma, Blood, 115:3008-3016, PMCID: PMC2858478
185. Rauch DA, Hurchla MA, Harding JC, Deng H, Shea L, Eagleton MC, Niewiesk S, Lairmore M, Piwnica-Worms D, Rosol T, Weber JD, Ratner L, Weilbaecher K. 2010. The Arf tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLOS One, 5:e15755. PMCID: PMC3012707
2011
186. Choudhary G, Ratner L. The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30II mRNA. Virology, 2011; 410: 307-315. PMCID: PMC3034254
187. Pan H, Ivashyna O, Sinha B, Lanza GM, Ratner L, Schlesinger PH, Wickline SA. Post-formulation peptide drug loading of nanostructures for metered control of NF-kB signaling. Biomaterials, 32: 231-238.PMCID: PMC2997356
188. Seegulam, ME, Ratner L. Integrase inhibitors effective againt human T-cell leukemia virus type 1. Antimicrobial Agents and Chemotherapy. 2011; 55:2011-7, PMCID: PMC3088187
2012
189. Ramachandiran S, Cain J, Liao A, He Y, Guo, X, Boise L, Fu H, Ratner L, Khoury HJ, and Bernal-Mizrachi L. 2012. The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV AND HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leukemia Research, 36:784-790. PMCID:PMC3331941
190. Belshan M, Kimata J, Brown C, Cheng X, McCulley A, Larsen A, Thippeshappa R, Hodara V, Giavedoni L, Hirsch V, Ratner L. 2012. Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology, 9:32. PMCID:PMC3353869
191. McCulley A, Ratner L. 2012. HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. Virology, 427:67-75 PMCID:PMC3302174.
192. Zane L, Yasunaga J, Mitagami Y, Matsuoka M, Yedavalli V, Tan S-W, Ratner L, Liu X, and Jeang KT. 2012. Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. RetroVirology, 9:114. PMCID: PMC3532233
193. Levine AM, Noy A, Lee J, Cesarman E, Ramos JC, Henry D, Sparano J, Reid E, Mitsuyasu R, Dezube B, Ratner L, Tulpule A. 2012. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. Journal of Clinical Oncology, 31: 58-64 PMCID: PMC3530691
2013
194. Bayraktar UD, Petrich A, Gupta N, Lensing S, Moore P, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Stier E, Henry DH, Barr P, Noy A. 2013. Outcome of patients with relapsed/refractory AIDS-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leukemia & Lymphoma, 53:2383-2389. PMCID: PMC3458169
195. Hood JL, Jallouk AP, Campbell N, Ratner L, Wickline SA. 2013. Cytolytic nanoparticles attenuate HIV-1 infectivity. Antiviral Therapy, 18: 95-103. PMID: 22954649
196. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera J-M, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson W, Wyen C, Oriol A, Navarro J-T, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Oksenhendler E, Remick SC, Sparano MA. 2013. Treatment factors affecting outcomes in HIV associated non-Hodgkin’s lymphomas: a pooled analysis of 1546 patients. Blood, 122:3251-3262. PMID: 24014242, PMCID:PMC3821722
197. Cachat A, Chevalier S, Alais S, Ko NL, Ratner L, Journo C, Dutarre H, Mahieux R. Alpha interferon restricts HTLV-1 and HTLV-2 de novo infection through PKR activation, 2013. J Virology, 87:13386-13396. PMID:24089560; PMCID:PMC3838277
198. Hou KK, Pan H, Ratner L, Schlesinger PH, and Wickline SA. 2013. Mechanisms of Nanoparticle-Mediated siRNA Transfection by Melittin-Derived Peptides.. ACS Nano, 7:8605-15. PMID: 24053333
2014
199. Rudek MA Moore PC, Mitsuyasu RT, Dezube B, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. 2014. A phase I/Pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy (HAART) in HIV-positive patients with cancer, Cancer, Cancer. 2014 Apr 15;120(8):1194-202. PMID:24474568; PMCID:PMC4038645
200. Rauch DA, Harding JC, Ratner L. 2014. IL-15 deficient Tax mice reveal a role for IL-1alpha in tumor immunity. PLOS One, 9:e85028, PMID: 24416335, PMCID: PMC3885672
201. Cheng X, Ratner L 2014. HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J Biological Chemistry, 289:9146-9157 PMID:24532789, PMCID: PMC3979364
2015
202. Kyei GB, Cheng X, Ramani, R, Ratner L. 2015. Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe, 17:98-106 , PMID: 25532805, PMCID: PMC4297224.
203. Noy A, Lee J, Cesarman E, Ambinder R, Baoicchi R, Reid E, Ratner L, Wagner N, Kaplan L. 2015. AMC048: Modified CODOX-M/IVAC with rituximab for untreated HIV-associated Burkitt lymphoma has high cure rates with improved toxicity. Blood, 126:160-166. PMID: 25957391
204. Baydoun HH, Cherian MA, Green PL, Ratner L. 2015. Inducible nitric oxide synthase mediates DNA double strand breaks in HTLV-1 induced leukemia/lymphoma Retrovirology, 12:71. PMID: 26265053, PMCID: PMC4534112
205. Romeo MM, Ko B, Kim J, Brady R, Heatley HC, He J, Harrod CK, Barnett B, Ratner L, Lairmore MD, Martinez E, Luscher B, Robson, CN, Henriksso M, Harrod R. 2015. Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30II accessory protein and the induction of oncogenic cellular transformation by p30II/c-MYC, Virology, 476:271-278, PMID:25569455.
206. Pujari R, Hunte, R, Remyvi M, Rauch D, Ratner L, Ramos JC, Takai Y, Nyborg J, ShembadeN. 2015. Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-kappaB inhibitor A20 and constitutive NF-kappaB signaling. PLOS Pathogens. 11: e1004721, PMID:25774694, PMCID: PMC4361615
207. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera J-M, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA, 2015. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma, Ann Oncol, 26:958-966. PMID: 2563207
208. Noy A, Lensing SY, Moore, PC, Gupta N, Aboulafia D, Ambinder R, Baiocchi R, Dezube B, Henry D,. Kaplan L, Levine A, Mitsuyasu, Ratner L, Reid E, Remick S, Sparano J, Tzachanis D, Wachsman W, Chadburn A. Plasmablastic lymphoma is curable in the HAART era. A 10 yr retrospective by the AIDS Malignancy Consortium (AMC), Leukemia Lymphoma 57:1731-1734. PMID:26674561.
209. Cherian M, Baydoun H, Al-Saleem J, Kvaratskhelia M, Green P, Ratner L. 2015. Akt activation by human T-cell leukemia virus Tax oncoprotein. J Biological Chemistry, 290:26270-26281. PMID:26324707
2016
210. Yeh C-H, Bai XT, Moles, R, Ratner L, Toshiki W, Nicot C. Mutation of Epigenetic Regulators and Loss of Function of TET2 and MLL3 in Patients with Acute Adult T-cell Leukemia. 2016. Molecular Cancer. 15:12943. PMID:26880370.
211. Murphy J, Hall WW, Ratner L, Sheehy N. Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: implications for the HTLV lifecycles. Virology, 494:129-142.
212. Zhang J, Gao X, Martin J, Rosa B, Chen Z, Mitreva M, Henrich T, Kuritzkes D, Ratner L. Evolution of coreceptor utilization to escape CCR5 antagonist therapy. Virology, 494:198-214, PMID:27128349
213. Ratner L, Rauch D, Abel H, Caruso B, Baydoun HH, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, Harding J, Cheng X, Jacobson S. 2016. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated T-cell leukemia lymphoma. Blood Cancer Journal, 6:e408, PMID:27015285
214. Sparano, JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Kachnic L, Fitzgerald TJ, Mitsuyasu R. 2016. Cetuximab plus chemoradiotherapy for human immunodeficiency virus-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial (AMC 045). J Clinical Oncology 35:727-733, PMID:27937092.
2017
215. Wagner-Johnston ND, Lensing S, Noy A, Ratner L, Henry D, Lee JY, Silver S, Faham M, Ambinder RF. 2017. High Frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: Prospective Multicenter Trial of the AIDS Malignancies Consortium (AMC 064). Leukemia & Lymphoma, 58:2939-2942, PMID:28508728
216. Albert B, Niu A, Ramani R, Williams RM, Marshall GR, Wender P, Williams RM, Ratner L, Barnes AB, Kyei G. 2017. Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkeable potency to activate latent HIV without global T-cell activation, Science Reports, 7:7456. PMID:28785069; PMCID: PMC5547048
217. Esser AK, Rauch D. Xiang J, Harding J, Kohart N, Ross M, Su X, Wu K, Huey D, Su Y, Green P, Rosol T, Niewiesk S, Ratner L, Weilbaecher K. 2017. HTLV-1 Viral Oncogene HBZ Induces Osteolytic Bone Disease in Transgenic Mice, Oncotarget, 27;8:69250-69263.
2018
218. Huey D, Bolon B, LaPerle KMD, Kannian P, Jacobson S, Ratner L, Green P, Niewiesk S. 2018. Role of wild type and recombinant human T cell leukemia viruses in humanized NSG mice. Comparative Medicine 68:4-14. PMID: 29460716
219. Rubinstein PG, Moore P, Henry DH, Ramos JC, Ratner L, Reid E, Sharon E, Noy A. 2018. Brentuximab vedotin with AVD shows safety and activity in newly diagnosed HIV-associated Hodgkin lymphoma (AMC 085). AIDS. 32:605-611. PMID: 29280762
220. Romeo M, Hutchinson T, Halu A, White Av, Kim J, Gardner R, Smith K, Nelson K, Bergeson R, McKee R, Harrod C, Ikezoe T, Ratner L, Luscher B, Martinez E, Harrod R. The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.Virology 518:103-115. PMID: 29462755
221. Kyei GB, Meng S, Ramani R, Niu A, Lagisetti C, Webb TR, Ratner L. Splicing factor 3B subunit 1 interacts with HIV Tat and plays a role in viral transcription and latency. mBio. 9:e01423-18, PMID: 30401776
222. Ramos JC, Sparano JA, Rudek M, Moore PC, Cesarman E, Reid EG, Henry D, Ratner L, Aboulafia D, Lee JY, Mitsuyasu R, Noy A. 2018. Safety and Preliminary Efficacy of Vorinostat with R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075). Clinical Lymphoma, Myeloma and Leukemia18:180-190.PMID: 29426719
223. Peres E, Blin J, Ricci EP, Artesi M, vanDen Broeke A, Corbin A, Gazzolo L, Ratner L, Jalinot P, Duc Dodon M. 2018. PDZ domain-binding motif of Tax sustains T-cell proliferation in HTLV-1-infected humanized mice. Cell Host & Microbe, 14:e1006933. PMID: 29566098
224. Cherian MA, Olson S, Cates K, Sundaramoorthi H, Cheng X, Harding J, Martens A, Challen GA, Tyagi M, Ratner L, Rauch D. 2018. An activating mutation of interferon regulatory factor 4, unique to adult T cell leukemia, J Biological Chemistry, 293:6844-6858, PMID:29540473.
225. Ratner L, Waldmann TA, Janakiram M, Brammer J. 2018. PD-1 inhibition promotes rapid adult T cell leukemia progression. N Engl J Med, 378:1947-1948, PMID: 29768155; Response by Ratner L, N Engl J Med, 379:696-697 PMID:30110590
226. Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A, Ye H, Janakiram M. 2018. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies, Blood, 132:1507-1518. PMID: 30104217
2019
227. Cao S, Wylie KM, Wyczalkowski MA, Karpova A, Ley J, Sun S, Mashl RJ, Liang WW, Wang X, Johnson K, DiPersio JF, Gay H, Ratner L, Chen F, Adkins DR, Ding L. 2019. Dynamic host immune response in virus-associated cancers. Commun Biol. 2019 2:109. PMID: 30911684
228. Malu A, Hutchison T, Yapindi L, Smith K, Nelson K, Bergeson R, Pope J, Romeo M, Harrod C, Ratner L, vanLint C, Harrod R. 2019. The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-kappa-B p65RelA-Stathmin complexes and causes mitotic spindle damage and genomic-instability by HTLV-1 Tax. Virology, 535:83-101, PMID:31299491.
229. Wu E, Du Y, Gao X, Zhang J, Martin J, Mitreva M, Ratner L. 2019. V1 and V2 domains of HIV envelope contribute to CCR5 antagonist resistance. J Virology, 93:e00050-19. PMID: 30787151. PMC6475789
230. Xiang J, Rauch DA, Huey DD, Panfil AR, Cheng X, Harding JC, Su X, Fontana F, Xu Y, Fox GC, Esser AK, Sundaramoorthi H, Wong W-H, Jia J, Rosol TJ, Veis D, Green PL, Niewiesk S, Ratner L, Weilbeacher KN. HTLV-1 Viral Oncogene HBZ Induces Lymphoproliferative and Osteolytic Bone Disease in Humanized Mouse Model, J Clin Investig, Insight, 4. pii: 128713. PMID:3157830
231. Al-Saleem J, Dirksen WP, Martinez MP, Shkriabai N, Kvaratskhelia M, Ratner L, Green PL. 2019. HTLV-1 Tax-1 interacts with SNX27 to regulate cellular localization of the HTLV-1 receptor molecule, GLUT1. PLoS One, 14:e0214059. PMID:30897179
232. Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang XX, Ren X, Olson S, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, Griffith M, Waldmann TA, Ratner L. 2019. Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade. Blood, 134:1406-14. PMID:31467059.
233. Martinez MP, Cheng X, Joseph A, Al-Saleem J, Panfil AR, Palettas M, Dirksen WP, Ratner L, Green PL 2019. HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo. HTLV-1. Retrovirology. 16: 44. PMID:31864373 PMCID: PMC6925871
2020
234. Kisaka JK. Ratner L, Kyei GB. 2020. The dual-specificity kinase DYRK1A modulates the levels of cyclin L2 to control HIV replication in macrophages. Journal of Virology, 94:e01583-19. PMID: 31852782. PMCID: PMC7158737
235. Ramos JC, Sparano JC, Reid EG, Ambinder RF, Siegel E, Moore PC, Chadburn A,. Rubinstein P, Durand C, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A, and the AIDS Malignancy Consortiium (AMC). 2020. Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial). Blood, 246: 1284-1297. PMID: 32430507
236. Rauch DA, Olson, S, Harding JC, Sundaramoorthi H, Kim, Y, Zhou T, MacLeod R, Challen G, Ratner L. 2020. IRF4 as a Therapeutic Target in Adult T Cell Leukemia Lymphoma, Retrovirology, 17:27. PMID: 32859220. PMC 7456374.
2021
237. Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. 2021. Response-Adapted Therapy with Infusional EPOCH Chemotherapy plus Rituximab in HIV-Associated, B-cell Non-Hodgkin’s Lymphoma. Haematologica. 106:730-735. PMID: 32107337
238. Bellon M, BialukI, Veronica G, Bai X-T, BruneauJ, Farre L, Bittencourt A, Marcais A, Petrus MN, Bangham C, Ratner L, Waldmann TA, Asnafi V, Gessain A, Matsuoka M, Franchini G, Hermine O, Watanabe T Nicot C. 2021. Germinal epimutation of FHIT is associated with progression to acute and chronic ATL diseases. Molecular Cancer, 20:86 PMID 34092254 PMC8183032.
239. Cheng X, Joseph A, Castro V, Chen-liaw A, Skidmore Z, Ueno T, Fujisawa J-I, Rauch DA, Challen G, Martinez MP Green P, Griffith M, Payton JE, Edwards J, Ratner L. 2021. CTCF regulation of HTLV-1 DNA methylation and gene expression. PLoS Pathogens.17:e1009577, PMID:34019588.
240. Rauch DA, Harding JC, Ratner L, Wickline SA, Pan H. 2021. Targeting NF-κB with nanotherapy in a mouse model adult T-cell leukemia/lymphoma. Nanoparticles 11:1582, PMID:34208564. PMCID: PMC8234599.
2022
241. Xiang J, Lu M, Shi M, Cheng X, Kwakwa K, Davis J, Su X, Bakewell S, Fontana F, Zhang Y, Xu Y, Veis D, DiPersio J, Ratner L, Sanderson R, Noseda A, Mollah S, Li J, Weilbaecher KN. Heparanase blockade as a novel dual-targeting therapy for COVID-19. Journal of Virology. 96:e0005722. PMID: 35319225
242. Haigentz M, Moore P, Birnali M, Cooley T, Sparano J, Rudek M, Ratner L, Henry D, Ramo JC, Deeken J, Rubinstein P, Chiao E. Safety and tolerability of carboplatin and paclitaxel in cancer patients with human immunodeficiency virus infection (AMC-078), An AIDS Malignancy Consortium (AMC) Study. Oncologist. 27:623-624, PMID: 35429391
243. Bagegni NA, Park H, Kraft K, O’Toole M, Gao F, Waqar S, Ratner L, Moregensztern D, Devarakonda S, Amin M, Baggstrom M, Liang C. Selvaggi G, Wang-Gillam A. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 89:487-497.PMID: 35247086
244. Du Y, Wu E, Gao X, Zhang J, Martin JC, Rosa B, Mitreva M, Ratner L. 2022. HIV-1 envelope sequence evolution with co-receptor antagonism. Microbiology Spectrum, 10:e0072522. PMID:35727047.
245. Poondru S, Joseph A, Harding JC, Sundaramoorthi H, Mehta-Shah N, Green G, Hassan A, Rauch DA, Ratner L. 2022. Adult T-Cell Leukemia-Lymphoma Presenting Concurrently with Myelopathy. Case Reports in Oncology. 15:918-926. PMID: 36636671
246. Wang-Gillam A, Lim K-Hu, McWilliams R, Suresh R, Lockhart A, Brown A, Brenden M, Belle J, Herndon J, Pederson K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon H, Zhu M, Trikalinos N, Ratner L, Aranha O, Hawkins W, Herzog B, Denardo D. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study. Cancer Chemotherapy Pharmacology 89:487-497. PMID: 35247086. PMCID: PMC8956523.
2023
247. Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Barta S, Bartlett NL, Bethony J, Bhatia K, Bowen J, Bryan AC, Cesarman E, Casper C, Cruz M, Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T, Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R, Leal FE, Lee M, Martin JP, Martin M-R, Mbulaiteye SM, Mitsuyasu R, Morris V, Mullighan CG, Mungall, AJ, Mungall K, Mutyaba I, Nokta M, Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H, Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynold SJ, Rubinstein P, Silver S, Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood, 141: 904-916, PMID: 36201743
248. Rubinstein PG, MoorePC, Bimali M, Rudek MA, Chadburn A, Ratner L, Henry, DH, Cesarman E, DeMarco CA, Costagliola D, Taoukik Y, Ramos JC, Sharon E, Ambinder RF, Reid EG, Mounier n, Besson C, and Noy A for the AIDS Malignancy Consortium (AMC) and the Lymphoma Study Association (LYSA) Brentuximab Vedotin with AVD for stage II-IV HIV-associated cHL, Lancet Hematology, 10:e624-e632, PMID: 37532416.
249. Gang M, Gao F, Poondru S, Thomas T, Ratner L. Clinical Characteristics and Outcomes of Infection with Human T-cell Lymphotropic Virus (HTLV) in a Non-endemic Area: A Single Institution Study. Frontiers in Microbiology. 14:1187697. PMID: 37426028. PMCID: PMC10324566
250. Auberle C, Gao F, Wu N, Kornfeld S, Picus J, Adkins D, Blinder M, Welch J, Saif-Ur-Rehman S, Stockerl-Goldstein K, Mehta-Shah N, DiPersio J, Waqar SN, Ratner L. Integration of clinical investigation in Hematology and Oncology fellowship training Academic Medicine, Submitted
251. Rajdev L, Wang C-CJ, Joshi H, Lensing H, Lee J, Ramo JC, Baiocchi R, Ratner L, Rubinstein P, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Dittmer DP, Einstein MH, Cesarman E, Mitsuytasu R, Sparano JA, AIDS Malignancy Consortium. Assessment of the Safety of Nivolumab in People Living With HIV With Advanced Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. JAMA Oncology. Submitted.
252. Haigentz M, Lee JH, Chiao EY, Aboulafia DM, Ratner L, Ambinder RF, Baiocchi R, Mitsuyasu RT, Wachsman W, Sparano JA, Rudek MA. Phase I trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4 interacting antiretroviral therapy in people living with human immunodeficiency virus infection and advanced cancer. Clinical Cancer Research, In press.
253. Tu JJ, King E, Maksimova V, Sith S, Macias, R, Cheng X, Yu L, Ratner L, Green PL, Niewiesk S, Richner J, Panfil AR. 2023. An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits. Journal of Virology, Submitted.
254. Rauch D, Cherian M, Cates K, Harding J, Sundaramoorthi H, Cheng X, Martens A, Challen G, Ratner L. N-myc transcription is derepressed in adult T cell leukemia, Submitted
255. Rauch DA, Olson S, Harding J, Kajimoto T, Van A, Challen G, Newton A, Ratner L. Protein kinase Cbeta is a therapeutic target for adult T-cell leukemia lymphoma. Blood Advances. Submitted
256. Rauch DA, Valino Ramos P, Harding J, Ratner L. Single-Cell Transcriptomic Analysis of Kaposi’s Sarcoma, In preparation
257. Joseph A, Cheng X, Rauch DA, Harding J, Ratner L. Role of CTCF Interaction with Human T-Cell Leukemia Virus Transformation. In preparation.